GB Sciences, Inc. (GBLX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.42 Million USD | 15.06% |
| 2022 | -1.67 Million USD | 10.51% |
| 2021 | -1.86 Million USD | 6.64% |
| 2020 | -2 Million USD | 83.33% |
| 2019 | -12.01 Million USD | 22.98% |
| 2018 | -15.59 Million USD | 12.51% |
| 2017 | -17.82 Million USD | -99.53% |
| 2016 | -8.93 Million USD | -28.37% |
| 2015 | -6.95 Million USD | 12.73% |
| 2014 | -7.97 Million USD | -4146.83% |
| 2013 | -187.76 Thousand USD | -68.07% |
| 2012 | -111.71 Thousand USD | -8.63% |
| 2011 | -102.84 Thousand USD | 73.18% |
| 2010 | -383.42 Thousand USD | 85.45% |
| 2009 | -2.63 Million USD | -2159.91% |
| 2008 | -116.62 Thousand USD | 22.52% |
| 2007 | -150.51 Thousand USD | 72.69% |
| 2006 | -551.07 Thousand USD | -24.42% |
| 2005 | -442.89 Thousand USD | -31.13% |
| 2004 | -337.74 Thousand USD | -376.46% |
| 2003 | -70.88 Thousand USD | 6.11% |
| 2002 | -75.5 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q1 | -265.12 Thousand USD | 49.94% |
| 2023 Q3 | -234 Thousand USD | 57.57% |
| 2023 Q4 | -369.89 Thousand USD | -58.07% |
| 2023 FY | -1.42 Million USD | 15.06% |
| 2023 Q2 | -551.49 Thousand USD | -108.01% |
| 2022 Q3 | -407.3 Thousand USD | -47.66% |
| 2022 Q4 | -529.62 Thousand USD | -30.03% |
| 2022 FY | -1.67 Million USD | 10.51% |
| 2022 Q1 | -459.51 Thousand USD | -1.89% |
| 2022 Q2 | -275.83 Thousand USD | 39.97% |
| 2021 Q2 | -411.54 Thousand USD | 16.59% |
| 2021 Q3 | -512.78 Thousand USD | -24.6% |
| 2021 Q4 | -450.99 Thousand USD | 12.05% |
| 2021 FY | -1.86 Million USD | 6.64% |
| 2021 Q1 | -493.4 Thousand USD | -52.22% |
| 2020 FY | -2 Million USD | 83.33% |
| 2020 Q1 | -745.3 Thousand USD | 87.53% |
| 2020 Q4 | -324.13 Thousand USD | 51.64% |
| 2020 Q2 | -491.81 Thousand USD | 34.01% |
| 2020 Q3 | -670.31 Thousand USD | -36.29% |
| 2019 Q2 | -2.08 Million USD | -5.44% |
| 2019 FY | -12.01 Million USD | 22.98% |
| 2019 Q1 | -1.98 Million USD | 61.32% |
| 2019 Q3 | -2.16 Million USD | -3.72% |
| 2019 Q4 | -5.97 Million USD | -175.81% |
| 2018 Q4 | -5.12 Million USD | -97.77% |
| 2018 Q1 | -3.72 Million USD | 39.12% |
| 2018 Q3 | -2.58 Million USD | 37.67% |
| 2018 Q2 | -4.15 Million USD | -11.41% |
| 2018 FY | -15.59 Million USD | 12.51% |
| 2017 Q3 | -6.21 Million USD | -135.36% |
| 2017 Q1 | -2.82 Million USD | -22.88% |
| 2017 FY | -17.82 Million USD | -99.53% |
| 2017 Q4 | -6.12 Million USD | 1.52% |
| 2017 Q2 | -2.64 Million USD | 6.31% |
| 2016 FY | -8.93 Million USD | -28.37% |
| 2016 Q4 | -2.29 Million USD | 28.61% |
| 2016 Q2 | -2.19 Million USD | -81.95% |
| 2016 Q1 | -1.2 Million USD | 25.17% |
| 2016 Q3 | -3.21 Million USD | -46.3% |
| 2015 Q2 | -2.69 Million USD | -76.86% |
| 2015 FY | -6.95 Million USD | 12.73% |
| 2015 Q1 | -1.52 Million USD | 62.13% |
| 2015 Q4 | -1.61 Million USD | -42.98% |
| 2015 Q3 | -1.12 Million USD | 58.08% |
| 2014 Q1 | -1.49 Million USD | -1037.13% |
| 2014 Q4 | -4.02 Million USD | -493.26% |
| 2014 FY | -7.97 Million USD | -4146.83% |
| 2014 Q3 | -677.73 Thousand USD | 61.93% |
| 2014 Q2 | -1.78 Million USD | -19.06% |
| 2013 Q3 | -12.8 Thousand USD | 8.45% |
| 2013 Q2 | -13.98 Thousand USD | 52.58% |
| 2013 Q1 | -29.48 Thousand USD | 47.72% |
| 2013 FY | -187.76 Thousand USD | -68.07% |
| 2013 Q4 | -131.48 Thousand USD | -927.18% |
| 2012 Q1 | -31.68 Thousand USD | -417.8% |
| 2012 Q4 | -56.4 Thousand USD | -923.87% |
| 2012 FY | -111.71 Thousand USD | -8.63% |
| 2012 Q2 | -18.12 Thousand USD | 42.81% |
| 2012 Q3 | -5509.00 USD | 69.6% |
| 2011 Q2 | -21.93 Thousand USD | 61.37% |
| 2011 Q3 | -18.02 Thousand USD | 17.81% |
| 2011 Q4 | -6119.00 USD | 66.05% |
| 2011 FY | -102.84 Thousand USD | 73.18% |
| 2011 Q1 | -56.76 Thousand USD | -150.45% |
| 2010 Q4 | -22.66 Thousand USD | 71.57% |
| 2010 Q1 | -221.17 Thousand USD | 24.44% |
| 2010 FY | -383.42 Thousand USD | 85.45% |
| 2010 Q3 | -79.71 Thousand USD | -33.16% |
| 2010 Q2 | -59.86 Thousand USD | 72.93% |
| 2009 Q2 | -1.91 Million USD | -8423.48% |
| 2009 Q3 | -404.33 Thousand USD | 78.9% |
| 2009 Q4 | -292.7 Thousand USD | 27.61% |
| 2009 FY | -2.63 Million USD | -2159.91% |
| 2009 Q1 | -22.47 Thousand USD | 30.97% |
| 2008 Q2 | -19.14 Thousand USD | 61.09% |
| 2008 Q3 | -15.71 Thousand USD | 17.92% |
| 2008 FY | -116.62 Thousand USD | 22.52% |
| 2008 Q4 | -32.56 Thousand USD | -107.23% |
| 2008 Q1 | -49.2 Thousand USD | -12.69% |
| 2007 Q3 | -31.57 Thousand USD | -279.72% |
| 2007 Q4 | -43.66 Thousand USD | -38.26% |
| 2007 Q2 | 17.57 Thousand USD | 118.92% |
| 2007 Q1 | -92.85 Thousand USD | 73.58% |
| 2007 FY | -150.51 Thousand USD | 72.69% |
| 2006 Q4 | -351.48 Thousand USD | -2101.98% |
| 2006 Q2 | -69.3 Thousand USD | 55.47% |
| 2006 FY | -551.07 Thousand USD | -24.42% |
| 2006 Q1 | -155.64 Thousand USD | 16.99% |
| 2006 Q3 | -15.96 Thousand USD | 76.97% |
| 2005 Q1 | -82.97 Thousand USD | 2.18% |
| 2005 FY | -442.89 Thousand USD | -31.13% |
| 2005 Q3 | -82.29 Thousand USD | 8.69% |
| 2005 Q2 | -90.12 Thousand USD | -8.63% |
| 2005 Q4 | -187.49 Thousand USD | -127.83% |
| 2004 Q4 | -84.82 Thousand USD | 51.38% |
| 2004 Q3 | -174.45 Thousand USD | -122.33% |
| 2004 Q1 | -12.5 Thousand USD | 47.02% |
| 2004 Q2 | -78.46 Thousand USD | -527.67% |
| 2004 FY | -337.74 Thousand USD | -376.46% |
| 2003 Q3 | -13.68 Thousand USD | -3.13% |
| 2003 FY | -70.88 Thousand USD | 6.11% |
| 2003 Q4 | -23.59 Thousand USD | -72.45% |
| 2003 Q1 | -20.34 Thousand USD | -24.28% |
| 2003 Q2 | -13.26 Thousand USD | 34.78% |
| 2002 Q3 | -29.44 Thousand USD | -113.26% |
| 2002 FY | -75.5 Thousand USD | 0.0% |
| 2002 Q4 | -16.36 Thousand USD | 44.4% |
| 2002 Q1 | -15.89 Thousand USD | 0.0% |
| 2002 Q2 | -13.8 Thousand USD | 13.12% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -6.371% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 71.84% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 92.041% |
| Nascent Biotech, Inc. | -2.22 Million USD | 36.297% |
| Rebus Holdings, Inc. | -664 Thousand USD | -113.932% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 101.735% |
| Qrons Inc. | -643.67 Thousand USD | -120.687% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -264.635% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 97.441% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -241.897% |
| Skye Bioscience, Inc. | -13.67 Million USD | 89.61% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 98.021% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 128.903% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -442.747% |
| SQZ Biotechnologies Company | -75.82 Million USD | 98.127% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 50.166% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 7.522% |
| Mesoblast Limited | -84.14 Million USD | 98.312% |
| Marizyme, Inc. | -34.08 Million USD | 95.833% |
| Genus plc | 6.4 Million USD | 122.195% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 114.581% |
| Pharming Group N.V. | -4.87 Million USD | 70.888% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 28.491% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -52.517% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 82.988% |
| ContraFect Corporation | -56.88 Million USD | 97.503% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 68.812% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1.321% |
| IMV Inc. | -38.67 Million USD | 96.327% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 48.361% |
| MultiCell Technologies, Inc. | -722.81 USD | -196425.92% |
| ONE Bio Corp. | 13.68 Million USD | 110.383% |
| Accustem Sciences Inc. | -3.74 Million USD | 62.084% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 97.592% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -194.063% |
| Q BioMed Inc. | -3.44 Million USD | 58.773% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 140.127% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 45.937% |
| Biomind Labs Inc. | -1 Million USD | -40.7% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 97.416% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 51.038% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 78.633% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 23.808% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -4642.618% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 91.049% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 26.498% |
| Alpha Cognition Inc. | -9.7 Million USD | 85.364% |
| HST Global, Inc. | -140.9 Thousand USD | -908.118% |
| CSL Limited | 3.7 Billion USD | 100.038% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -26.278% |
| Halberd Corporation | -75.05 Thousand USD | -1792.75% |
| Enzolytics Inc. | -2.14 Million USD | 33.893% |
| Agentix Corp. | -1.37 Million USD | -3.554% |
| Resverlogix Corp. | -12.74 Million USD | 88.858% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 55.165% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.666% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -36.064% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 51.343% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 10.058% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 58.281% |
| AVAX Technologies, Inc. | 6.69 Million USD | 121.224% |
| Zenith Capital Corp. | -8.94 Million USD | 84.116% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.658% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -8054.004% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 42.146% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -728.239% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 29.143% |
| Kadimastem Ltd | -3.04 Million USD | 53.277% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -44.353% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -13.098% |
| BioStem Technologies, Inc. | -7.77 Million USD | 81.739% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -682.714% |
| LadRx Corporation | -3.82 Million USD | 62.849% |
| Cell Source, Inc. | -4.32 Million USD | 67.158% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -106.785% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -106.785% |
| NovAccess Global Inc. | -2.46 Million USD | 42.414% |
| Affymax, Inc. | -15.04 Million USD | 90.559% |
| Itoco Inc. | -919.14 Thousand USD | -54.548% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 66.485% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -26.945% |
| Mobile Lads Corp. | -554.55 Thousand USD | -156.155% |
| CytoDyn Inc. | -18.05 Million USD | 92.134% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -5543.659% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -545.457% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -151.541% |
| SYBLEU INC | -149.18 Thousand USD | -852.211% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 21.792% |
| International Stem Cell Corporation | -663 Thousand USD | -114.255% |
| Bioxytran, Inc. | -3.82 Million USD | 62.815% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2598.535% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -6883.82% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 96.083% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 12.206% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -93.047% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 54.339% |
| Neutra Corp. | -229.48 Thousand USD | -518.996% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 91.901% |
| PureTech Health plc | -146.19 Million USD | 99.028% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 93.39% |
| IXICO plc | -1.43 Million USD | 1.148% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 85.033% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 98.834% |
| CSL Limited | 3.81 Billion USD | 100.037% |
| Cellectis S.A. | -108.85 Million USD | 98.695% |